DK1301201T3 - Behandling af glycogenosis type II - Google Patents

Behandling af glycogenosis type II

Info

Publication number
DK1301201T3
DK1301201T3 DK01951000T DK01951000T DK1301201T3 DK 1301201 T3 DK1301201 T3 DK 1301201T3 DK 01951000 T DK01951000 T DK 01951000T DK 01951000 T DK01951000 T DK 01951000T DK 1301201 T3 DK1301201 T3 DK 1301201T3
Authority
DK
Denmark
Prior art keywords
treatment
glycogenosis type
storage disease
disease type
glycogen storage
Prior art date
Application number
DK01951000T
Other languages
Danish (da)
English (en)
Inventor
Yuan-Tsong Chen
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22818451&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1301201(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Duke filed Critical Univ Duke
Application granted granted Critical
Publication of DK1301201T3 publication Critical patent/DK1301201T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK01951000T 2000-07-18 2001-07-10 Behandling af glycogenosis type II DK1301201T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21923700P 2000-07-18 2000-07-18
PCT/US2001/021651 WO2002005841A1 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type ii

Publications (1)

Publication Number Publication Date
DK1301201T3 true DK1301201T3 (da) 2007-04-02

Family

ID=22818451

Family Applications (5)

Application Number Title Priority Date Filing Date
DK01951000T DK1301201T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenosis type II
DK07001091.3T DK1782825T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK18194771.4T DK3449934T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK14167882.1T DK2767291T3 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II
DK16178390.7T DK3108895T3 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II

Family Applications After (4)

Application Number Title Priority Date Filing Date
DK07001091.3T DK1782825T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK18194771.4T DK3449934T3 (da) 2000-07-18 2001-07-10 Behandling af glycogenlagringssygdom type II
DK14167882.1T DK2767291T3 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II
DK16178390.7T DK3108895T3 (en) 2000-07-18 2001-07-10 Treatment of glycogen storage disease type II

Country Status (17)

Country Link
US (10) US7056712B2 (https=)
EP (4) EP1301201B1 (https=)
JP (10) JP5113312B2 (https=)
AT (1) ATE355075T1 (https=)
AU (3) AU7194101A (https=)
BR (1) BR0113006A (https=)
CA (1) CA2416492C (https=)
CY (2) CY1120977T1 (https=)
DE (1) DE60126947T2 (https=)
DK (5) DK1301201T3 (https=)
ES (5) ES2599401T3 (https=)
LT (3) LT3449934T (https=)
MX (1) MXPA03000474A (https=)
PT (5) PT1782825E (https=)
SI (3) SI3108895T1 (https=)
TW (1) TWI280882B (https=)
WO (1) WO2002005841A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7194101A (en) * 2000-07-18 2002-01-30 Univ Duke Treatment of glycogen storage disease type ii
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
ATE384736T1 (de) * 2001-04-30 2008-02-15 Zystor Therapeutics Inc Subzelluläres targeting von therapeutischen proteinen
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US6981964B2 (en) 2001-05-22 2006-01-03 Boston Scientific Scimed, Inc. Draining bodily fluids with a stent
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US6733536B1 (en) 2002-10-22 2004-05-11 Scimed Life Systems Male urethral stent device
ATE521701T1 (de) 2003-01-22 2011-09-15 Univ Duke Verbesserte konstrukte zur expression lysosomaler polypeptide
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7129049B2 (en) * 2003-12-22 2006-10-31 Regents Of The University Of Minnesota Method of detecting equine glycogen storage disease IV
CN1922313B (zh) * 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
US20050208090A1 (en) * 2004-03-18 2005-09-22 Medtronic, Inc. Methods and systems for treatment of neurological diseases of the central nervous system
JP2008503590A (ja) * 2004-06-21 2008-02-07 メドトロニック・インコーポレーテッド 組成物を細胞にデリバリーするための医学用システム及び方法
US20090117091A1 (en) * 2006-11-13 2009-05-07 Lebowitz Jonathan Methods for treating pompe disease
WO2009075815A1 (en) 2007-12-07 2009-06-18 Duke University Immunomodulating gene therapy
HRP20170698T1 (hr) 2008-05-07 2017-09-22 Biomarin Pharmaceutical Inc. Lizosomski usmjereni peptidi i njihove uporabe
ES2535461T3 (es) * 2008-07-08 2015-05-11 Duke University Método de tratamiento de la enfermedad por almacenamiento de glucógeno
EP2475376B1 (en) * 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
WO2011139379A2 (en) 2010-05-06 2011-11-10 Duke University A method of treating patients undergoing protein replacement therapy, gene replacement therapy, or other therapeutic modalities
EP2981551B1 (en) 2013-02-20 2020-06-03 Valerion Therapeutics, LLC Methods and compositions for treatment of pompe disease
CN105377039A (zh) * 2013-05-15 2016-03-02 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
WO2016054231A1 (en) 2014-09-30 2016-04-07 Amicus Therapeutics, Inc. Highly potent acid alpha-glucosidase with enhanced carbohydrates
WO2016178431A1 (ja) * 2015-05-07 2016-11-10 国立大学法人 東京大学 ポリイオンコンプレックス型ポリマーソームを用いたナノリアクタとその製造方法
EP3344337A4 (en) * 2015-08-31 2019-03-06 Duke University METHOD AND COMPOSITIONS FOR TREATING CYTOPLASMATIC GLYCOGEN MEMORY DISEASES
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
KR102510941B1 (ko) 2015-12-30 2023-03-20 아미쿠스 세라퓨틱스, 인코포레이티드 폼페병 치료용의 강화된 산 알파-글루코시다제
IL325155A (en) 2016-03-30 2026-02-01 Amicus Therapeutics Inc Formulations containing recombinant acid alpha-glucosidase
US10227577B2 (en) 2016-03-30 2019-03-12 Amicus Therapeutics, Inc. Method for selection of high M6P recombinant proteins
IL305449B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Gene therapy for the treatment of mucocutaneous type ii diabetes
EP3624831B1 (en) 2017-05-15 2023-03-29 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
WO2020163480A1 (en) * 2019-02-05 2020-08-13 Amicus Therapeutics, Inc. Recombinant human acid alpha-glucosidase and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3063911A (en) * 1961-04-03 1962-11-13 Taisho Pharmaceutical Co Ltd Acid-stable digestive enzyme preparation and process of making same
US5464778A (en) 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5356804A (en) * 1990-10-24 1994-10-18 Mount Sinai School Of Medicine Of The City Of New York Cloning and expression of biologically active human α-galactosidase A
US6118045A (en) 1995-08-02 2000-09-12 Pharming B.V. Lysosomal proteins produced in the milk of transgenic animals
CA2328518A1 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
DK1137762T3 (da) 1998-12-07 2009-02-02 Genzyme Corp Behandling af Pompes sygdom
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
AU7194101A (en) * 2000-07-18 2002-01-30 Univ Duke Treatment of glycogen storage disease type ii
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
CN1922313B (zh) * 2004-02-10 2011-10-26 生物马林医药公司 酸性α-糖苷酶及其片段
US8470552B2 (en) 2009-10-12 2013-06-25 Keck Graduate Institute Strategy to reduce lactic acid production and control PH in animal cell culture

Also Published As

Publication number Publication date
ES2599401T3 (es) 2017-02-01
WO2002005841A1 (en) 2002-01-24
AU2001271941B2 (en) 2007-03-01
JP2018199721A (ja) 2018-12-20
HK1103363A1 (en) 2007-12-21
BR0113006A (pt) 2004-10-19
EP3449934B1 (en) 2020-05-20
EP2767291B1 (en) 2016-09-14
DE60126947T2 (de) 2007-10-31
ES2700865T3 (es) 2019-02-19
CY1123084T1 (el) 2021-10-29
US20210169996A1 (en) 2021-06-10
JP2008081507A (ja) 2008-04-10
JP2017137357A (ja) 2017-08-10
PT1301201E (pt) 2007-03-30
SI3449934T1 (sl) 2020-09-30
US20080175833A1 (en) 2008-07-24
JP6163216B2 (ja) 2017-07-12
DK3108895T3 (en) 2018-11-26
ATE355075T1 (de) 2006-03-15
PT3108895T (pt) 2018-12-18
TWI280882B (en) 2007-05-11
DK2767291T3 (en) 2016-12-05
JP2020019822A (ja) 2020-02-06
US9907839B2 (en) 2018-03-06
CA2416492A1 (en) 2002-01-24
HK1054690A1 (en) 2003-12-12
US20020110551A1 (en) 2002-08-15
EP3449934A1 (en) 2019-03-06
JP2013231081A (ja) 2013-11-14
DK1782825T3 (da) 2014-11-03
EP3108895A1 (en) 2016-12-28
EP3108895B1 (en) 2018-09-19
DE60126947D1 (de) 2007-04-12
JP2016056206A (ja) 2016-04-21
JP5113312B2 (ja) 2013-01-09
LT2767291T (lt) 2016-11-25
JP2012006953A (ja) 2012-01-12
CY1120977T1 (el) 2019-12-11
LT3449934T (lt) 2020-08-10
US20150004152A1 (en) 2015-01-01
US8900552B2 (en) 2014-12-02
SI2767291T1 (sl) 2016-11-30
ES2523024T3 (es) 2014-11-20
JP5792774B2 (ja) 2015-10-14
EP2767291A2 (en) 2014-08-20
ES2277931T3 (es) 2007-08-01
JP2018002749A (ja) 2018-01-11
US9370556B2 (en) 2016-06-21
ES2799882T3 (es) 2020-12-22
AU2010200487A1 (en) 2010-03-04
JP2014185187A (ja) 2014-10-02
US20050123531A1 (en) 2005-06-09
PT1782825E (pt) 2014-11-04
CA2416492C (en) 2008-04-29
MXPA03000474A (es) 2003-10-06
LT3108895T (lt) 2018-11-26
US20180185457A1 (en) 2018-07-05
AU7194101A (en) 2002-01-30
PT2767291T (pt) 2016-10-25
US20130195834A1 (en) 2013-08-01
US20100254966A1 (en) 2010-10-07
EP2767291A3 (en) 2014-10-08
US7056712B2 (en) 2006-06-06
SI3108895T1 (sl) 2019-01-31
US20120058132A1 (en) 2012-03-08
HK1197656A1 (en) 2015-02-06
EP1301201A1 (en) 2003-04-16
US10792341B2 (en) 2020-10-06
PT3449934T (pt) 2020-06-25
US20160184410A1 (en) 2016-06-30
EP1301201B1 (en) 2007-02-28
DK3449934T3 (da) 2020-06-29
JP2004503598A (ja) 2004-02-05

Similar Documents

Publication Publication Date Title
CY1123084T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
BRPI0418251A (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos para o tratamento de doenças virais
TR200401029T4 (tr) Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
NO20060971L (no) Pyridazinderivater og deres anvendelse som terapeutiske midler
EA200300171A1 (ru) Циклопентаноиндолы, композиции, содержащие данные соединения, и способы лечения
ATE245152T1 (de) Dioxocyclopentylhydroxamsäure
EA200401522A1 (ru) Противотуберкулёзный препарат: композиции и способы
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
DK2017276T3 (da) Phenylcarboxamid-forbindelser til behandling af smerte
WO2003063787A3 (en) Non-steroidal analogs of 2-methoxyestradiol
EA200400530A1 (ru) Перекрестно-сшитые антибиотики "гликопептид-цефалоспорин"
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
SE0003476D0 (sv) Compounds
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
ATE478688T1 (de) Verbindungen für den transfer von oligonukleotiden
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE344662T1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
NO20053876L (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
ATE502639T1 (de) 4-hydroxypiperidin-derivate zur verwendung als antimycobakterielle mittel
CY1118235T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ii